Given that the AKT/mTOR pathway lies downstream of IGF-1/IGF-1R signaling (71) and the success of combined mTOR/IGF-1R inhibition in sarcomas (72), future clinical trials could benefit from looking at a similar combined approach to chordoma management. The gene discussed is IGF1R; the disease is chordoma.